There has been a significant increase in the use of short-term percutaneous ventricular assist devices (pVADs) as acute circulatory support in cardiogenic shock and to provide haemodynamic support during interventional procedures, including high-risk percutaneous coronary interventions. Although frequently considered together, pVADs differ in their haemodynamic effects, management, indications, insertion techniques, and monitoring requirements. This consensus document summarizes the views of an expert panel by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) and appraises the value of short-term pVAD. It reviews the pathophysiological context and possible indications for pVAD in different clinical settings and provides guidance regarding the management of pVAD based on existing evidence and best current practice.
Bibliographical noteConflict of interest: A.C. received consulting fees/honoraria from Abiomed, Abbott Vascular, Cardinal Health, Biosensor, Magenta Medical. D.D. has served on the Scientific Advisory Board of Impella CP. A.C. received grants and personal fees from Getinge. J.E.M. received grants and personal fees from Abiomed and personal fees from Orion Pharma and Novartis. F.P. received personal fees from Abiomed. G.T. received personal fees from Abiomed and GADA. G.T. received personal fees from GE Healthcare. N.v.M. received grants and personal fees from Abbott Vascular, Medtronic, Boston Scientific, PulseCath BV. N.W. received personal fees and non-financial support from Abiomed. None of the other Authors has relevant conflicts of interest to disclose.
© Europa Digital & Publishing 2021. All rights reserved.